[Strategy for treating liver fibrosis by integration of the disease and its syndromes in traditional Chinese medicine].
The strategy for treating liver fibrosis in chronic hepatitis patients includes dispelling the etiological factors, inhibiting the inflammatory reaction, decreasing the sedimentation of extracellular matrix, accelerating the degradation of extracellular matrix, improving the microcirculatory and metabolic disturbance, and ameliorating the complicating diseases, etc. Researchers should pay attention to the liver function indexes in chronic liver disease in evaluating the therapeutic effects of anti-fibrosis. Effective etiological treatment should be considered as the first step in treating liver fibrosis in chronic hepatitis patients, and inhibiting the inflammatory reaction is one of the most important tactics for suppressing the development of fibrosis and for decreasing the incidence rate of liver cancer in chronic hepatitis patients. Treatment based on syndrome differentiation, a dynamic therapy aimed at the holistic pathological state, can improve the pathological state of the disease. It is especially important to take the advantages of the integration of traditional Chinese and western medicine in the clinical diagnostic and therapeutic procedure for increasing the therapeutic effect of live fibrosis.
Liu
Ping
P
Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. liuliver@online.sh.cn
D000998:Antiviral Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000628:therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000628:therapy*; D008516:Medicine, Chinese Traditional / Q000379:methods*; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D010982:Platelet-Derived Growth Factor / Q000187:drug effects / Q000378:metabolism; D013577:Syndrome; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000378:metabolism
D000998:Antiviral Agents; D004365:Drugs, Chinese Herbal; D010936:Plant Extracts; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D007372:Interferons